FDA approves Translational Sciences’ medical imaging software

By Michelle Lang

Recorded Future raises $12M to push its prediction tech [May 25, 2012]

38 Studios announces company-wide layoffs [May 24, 2012]

Mobiquity, FlightView join to make mobile airline app [May 24, 2012]

Data breaches a growing problem in healthcare [May 24, 2012]

Translational Sciences Corp., a Cambridge medical software firm, has won FDA approval to commercialize its OncoTrac medical imaging software, intended for assessing treatment options for metastatic tumors.

Quantitative assessments coming out of OncoTrac software may be used by companies in submitting data for FDA approval of anti-cancer drugs. According to the company, its assessments conform to clinical research standards and can be used by oncologists, radiologists and cancer patients alike. The data is exported and stored in electronic medical records and a Picture and Archive Communications System.

Originally developed at the German Cancer Research Center by Mint Medical GmbH, Translational Sciences’ OncoTrac is approved in Europe where it is sold as Mint Lesion.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.